SCHEMBL770493

SCHEMBL770493

O=C(NCCC(=O)N1CCC2CCCCC2C1)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.53
HTT P42858 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.51
ITGB3 P05106 3/20 0.51
ITGA2B P08514 3/20 0.51
CHRM1 P11229 3/20 0.51
CHRM5 P08912 2/20 0.49
DPP4 P27487 1/20 0.47
ALDH1A1 P00352 1/20 0.47
GAA P10253 1/20 0.47
RAB9A P51151 1/20 0.47
KMT2A Q03164 1/20 0.47
CHRM2 P08172 1/20 0.46
CHRM3 P20309 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL771597 0.83 ALDH1A1 (0.49) KDM4ESMN1; SMN2ALDH1A1KMT2A
SCHEMBL770891 0.82 KMT2A (0.49) DPP4ALDH1A1KMT2A
SCHEMBL771329 0.81 TDP1 (0.55) SMN1; SMN2ALDH1A1RAB9AKMT2A
SCHEMBL770994 0.81 RAB9A (0.55) KDM4ESMN1; SMN2CHRM1CHRM5ALDH1A1
SCHEMBL771029 0.81 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1RAB9AKMT2A
SCHEMBL771711 0.81 LMNA (0.49) SMN1; SMN2ALDH1A1KMT2A
SCHEMBL771031 0.81 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1RAB9AKMT2A
SCHEMBL770899 0.81 SMN1; SMN2 (0.48) HTTSMN1; SMN2CHRM5ALDH1A1RAB9A
SCHEMBL771125 0.80 SMN1; SMN2 (0.53) KDM4EHTTSMN1; SMN2CHRM5ALDH1A1
SCHEMBL770799 0.79 DPP4 (0.60) KDM4EHTTSMN1; SMN2CHRM1DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 KDM4E 4105/4885HTT 412/4885SMN1; SMN2 3653/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 KDM4E 4127/4885HTT 425/4885SMN1; SMN2 3637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.